Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 21.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 83,074 shares of the company’s stock after selling 22,839 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Pacira BioSciences were worth $1,250,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in PCRX. Pacer Advisors Inc. grew its stake in Pacira BioSciences by 129.4% during the 3rd quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock valued at $74,681,000 after purchasing an additional 2,799,434 shares in the last quarter. Fort Washington Investment Advisors Inc. OH bought a new position in Pacira BioSciences during the 2nd quarter worth approximately $13,240,000. Assenagon Asset Management S.A. boosted its holdings in Pacira BioSciences by 314.4% in the third quarter. Assenagon Asset Management S.A. now owns 553,114 shares of the company’s stock worth $8,324,000 after purchasing an additional 419,656 shares during the period. Doma Perpetual Capital Management LLC increased its stake in Pacira BioSciences by 71.8% during the second quarter. Doma Perpetual Capital Management LLC now owns 1,000,761 shares of the company’s stock valued at $28,632,000 after purchasing an additional 418,321 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its position in shares of Pacira BioSciences by 269.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock worth $5,955,000 after buying an additional 288,662 shares during the last quarter. 99.73% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have commented on PCRX shares. HC Wainwright restated a “buy” rating and issued a $39.00 target price on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Royal Bank of Canada upped their price objective on Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 7th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Pacira BioSciences in a research note on Friday, November 8th. Barclays lowered their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 12th. Finally, Jefferies Financial Group lifted their price objective on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $23.50.

Pacira BioSciences Price Performance

NASDAQ PCRX opened at $19.83 on Wednesday. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $35.95. The firm has a market capitalization of $915.61 million, a PE ratio of -9.77 and a beta of 0.80. The company’s 50 day simple moving average is $17.44 and its 200 day simple moving average is $18.82. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.